Source:http://linkedlifedata.com/resource/pubmed/id/16710719
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-11-28
|
pubmed:abstractText |
The melanoma differentiation-associated gene-7 (mda-7/IL-24) is a unique member of the interleukin 10 (IL-10) family of cytokines, with ubiquitous tumor cell pro-apoptotic activity. Recent data have shown that IL-24 is secreted as a glycosylated protein and functions as a pro-Th1 cytokine and as a potent anti-angiogenic molecule. In this study, we analyzed the activity of Ad-mda7 and its protein product, secreted IL-24, against human breast cancer cells. We show that Ad-mda7 transduction of human breast cancer cells results in G(2)/M phase cell cycle arrest and apoptotic cell death, which correlates with secretion of IL-24 protein. Neutralizing antibody against IL-24 significantly inhibited Ad-mda7 cytotoxicity. IL-24 and IL-10 both engage their cognate receptors on breast cancer cells resulting in phosphorylation and activation of STAT3, however, IL-10 receptor binding failed to induce cell killing, indicating that tumor cell killing by IL-24 is independent of STAT3 phosphorylation. Treatment with exogenous IL-24 induced apoptosis in breast cancer cells and this effect was abolished by addition of anti-IL-24 antibody or anti-IL-20R1, indicating that bystander cell killing is mediated via IL-24 binding to the IL-20R1/IL-20R2 heterodimeric receptor complex. Co-administration of the related cytokine IL-10 inhibited killing mediated by IL-24 and concomitantly inhibited IL-24 mediated up-regulation of the tumor suppressor proteins, p53 and p27(Kip1). In summary, we have defined a tumor-selective cytotoxic bystander role for secreted IL-24 protein and identified a novel receptor-mediated death pathway in breast cancer cells, wherein the related cytokines IL-24 and IL-10 exhibit antagonistic activity.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA 89778,
http://linkedlifedata.com/resource/pubmed/grant/CA06294,
http://linkedlifedata.com/resource/pubmed/grant/CA097598,
http://linkedlifedata.com/resource/pubmed/grant/CA102716,
http://linkedlifedata.com/resource/pubmed/grant/CA88421,
http://linkedlifedata.com/resource/pubmed/grant/P30 CA016672-30
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-20 receptor,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-24
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0340-7004
|
pubmed:author |
pubmed-author:BocangelDoraD,
pubmed-author:ChadaSunilS,
pubmed-author:DoneskeBlairB,
pubmed-author:EkmekciogluSuhendanS,
pubmed-author:GrimmElizabeth AEA,
pubmed-author:HuntKelly KKK,
pubmed-author:MhashilkarAbnerA,
pubmed-author:PoindexterNancyN,
pubmed-author:RameshRajagopalR,
pubmed-author:SuttonR BryanRB,
pubmed-author:ZhengMingzhongM
|
pubmed:issnType |
Print
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
205-15
|
pubmed:dateRevised |
2007-12-3
|
pubmed:meshHeading |
pubmed-meshheading:16710719-Apoptosis,
pubmed-meshheading:16710719-Breast Neoplasms,
pubmed-meshheading:16710719-Cell Line, Tumor,
pubmed-meshheading:16710719-Cell Proliferation,
pubmed-meshheading:16710719-Female,
pubmed-meshheading:16710719-Flow Cytometry,
pubmed-meshheading:16710719-Fluorescent Antibody Technique,
pubmed-meshheading:16710719-Gene Transfer Techniques,
pubmed-meshheading:16710719-Humans,
pubmed-meshheading:16710719-Interleukin-10,
pubmed-meshheading:16710719-Interleukins,
pubmed-meshheading:16710719-Receptors, Interleukin
|
pubmed:year |
2007
|
pubmed:articleTitle |
Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.
|
pubmed:affiliation |
Introgen Therapeutics Inc., 2250 Holcombe Boulevard, Houston, TX 77030, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|